The relationship between depression and metabolic control parameters in type 2 diabetic patients: A cross-sectional and feasibility interventional study.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
24
08
2020
accepted:
13
10
2020
pubmed:
25
10
2020
medline:
28
4
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
Substantial evidence supports a bidirectional relationship between diabetes and clinical depression. However, little is known about the effect of treating one condition on the control of the other. Thus, this study aimed to determine the prevalence of depression among Type II diabetes mellitus (T2DM) patients and to assess the efficacy and feasibility of escitalopram treatment of depression on their metabolic control parameters. T2DM patients attending primary care clinics in the North of Jordan were enrolled in a cross-sectional study during the period from February to December 2019 (n = 157). Depressive symptoms were screened utilising the patient health questionnaire-9 (PHQ-9) tool. Metabolic control was assessed by measurement of glycated haemoglobin (HbA1c), triglycerides, cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL). Patients with moderate to severe depressive symptoms by PHQ-9 (n = 58) were interviewed by a psychiatrist to confirm a clinical diagnosis of depression. Eligible depressed patients were administered escitalopram 10 mg orally once daily for 3 months (n = 12). Thereafter, depressive symptoms and metabolic control measures were reassessed. The prevalence of moderate to severe depressive symptoms among T2DM patients, according to PHQ-9, was 36.94%, while the prevalence of clinical depression based on interview was 7.64%. Baseline PHQ-9 scores correlated significantly with baseline levels of HbA1c, HDL, cholesterol and triglycerides. Escitalopram treatment intervention resulted in significant improvement of PHQ-9 scores without significantly improving any of the metabolic control measures. The relationship between depression and T2DM in the context of metabolic syndrome is plausible. However, our results show that escitalopram treatment may not be associated with significant improvement in metabolic control parameters among these patients. Our study has laid the groundwork for future randomised clinical trials with larger sample size and longer follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Substantial evidence supports a bidirectional relationship between diabetes and clinical depression. However, little is known about the effect of treating one condition on the control of the other. Thus, this study aimed to determine the prevalence of depression among Type II diabetes mellitus (T2DM) patients and to assess the efficacy and feasibility of escitalopram treatment of depression on their metabolic control parameters.
METHODS
METHODS
T2DM patients attending primary care clinics in the North of Jordan were enrolled in a cross-sectional study during the period from February to December 2019 (n = 157). Depressive symptoms were screened utilising the patient health questionnaire-9 (PHQ-9) tool. Metabolic control was assessed by measurement of glycated haemoglobin (HbA1c), triglycerides, cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL). Patients with moderate to severe depressive symptoms by PHQ-9 (n = 58) were interviewed by a psychiatrist to confirm a clinical diagnosis of depression. Eligible depressed patients were administered escitalopram 10 mg orally once daily for 3 months (n = 12). Thereafter, depressive symptoms and metabolic control measures were reassessed.
RESULTS
RESULTS
The prevalence of moderate to severe depressive symptoms among T2DM patients, according to PHQ-9, was 36.94%, while the prevalence of clinical depression based on interview was 7.64%. Baseline PHQ-9 scores correlated significantly with baseline levels of HbA1c, HDL, cholesterol and triglycerides. Escitalopram treatment intervention resulted in significant improvement of PHQ-9 scores without significantly improving any of the metabolic control measures.
CONCLUSION
CONCLUSIONS
The relationship between depression and T2DM in the context of metabolic syndrome is plausible. However, our results show that escitalopram treatment may not be associated with significant improvement in metabolic control parameters among these patients. Our study has laid the groundwork for future randomised clinical trials with larger sample size and longer follow-up.
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13777Subventions
Organisme : Jordan University of Science and Technology
ID : 232/2015
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
World Health Organization. Diabetes facts. https://www.who.int/news-room/fact-sheets/detail/diabetes.
NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet (London, England). 2016;387:1513-1530. https://doi.org/10.1016/S0140-6736(16)00618-8.
The World Bank. Jordan Country Reclassification-Questions and answers. https://www.worldbank.org/en/country/jordan/brief/qa-jordan-country-reclassification.
World Health Organization - Diabetes country profiles, 2016. https://www.who.int/diabetes/country-profiles/jor_en.pdf.
Mental Health America. Diabetes and Mental Health. https://www.mhanational.org/diabetes-and-mental-health.
Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care. 1993;16:1167-1178. https://doi.org/10.2337/diacare.16.8.1167.
Lin EH, Von Korff M, Alonso J, et al. Mental disorders among persons with diabetes-results from the World Mental Health Surveys. J Psychosom Res. 2008;65:571-580. https://doi.org/10.1016/j.jpsychores.2008.06.007.
Mendenhall E, Norris SA, Shidhaye R, Prabhakaran D. Depression and type 2 diabetes in low- and middle-income countries: a systematic review. Diabetes Res Clin Pract. 2014;103:276-285. https://doi.org/10.1016/j.diabres.2014.01.001.
Lopez-de-Andrés A, Jiménez-Trujillo MI, Hernández-Barrera V, et al. Trends in the prevalence of depression in hospitalized patients with type 2 diabetes in Spain: analysis of hospital discharge data from 2001 to 2011 [published correction appears in PLoS One. 2016;11(8):e0162227]. PLoS One. 2015;10:e0117346. Published 2015 Feb 23. https://doi.org/10.1371/journal.pone.0117346
Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care. 2002;25:464-470. https://doi.org/10.2337/diacare.25.3.464.
Palinkas LA, Barrett-Connor E, Wingard DL. Type 2 diabetes and depressive symptoms in older adults: a population-based study. Diabet Med. 1991;8:532-539. https://doi.org/10.1111/j.1464-5491.1991.tb01646.x.
Bai X, Liu Z, Li Z, Yan D. The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis. BMJ Open. 2018;8:e020062. Published 2018 Nov 28. https://doi.org/10.1136/bmjopen-2017-020062.
Al-Amer RM, Sobeh MM, Zayed AA, Al-Domi HA. Depression among adults with diabetes in Jordan: risk factors and relationship to blood sugar control. J Diabetes Complications. 2011;25:247-252. https://doi.org/10.1016/j.jdiacomp.2011.03.001.
Lustman PJ, Penckofer SM, Clouse RE. Recent advances in understanding depression in adults with diabetes. Curr Psychiatry Rep. 2008;10:495-502. https://doi.org/10.1007/s11920-008-0079-1.
Andreoulakis E, Hyphantis T, Kandylis D, Iacovides A. Depression in diabetes mellitus: a comprehensive review. Hippokratia. 2012;16:205-214.
Banwari G.Review article Comorbid depression and diabetes mellitus: a double whammy. 2013. https://www.semanticscholar.org/paper/Review-article-Comorbid-depression-and-diabetes-a-Banwari/da0dbb8b192a71a8772747bab33f246b82c25d65?p2df.
Vancampfort D, Mitchell AJ, De Hert M, et al. Type 2 diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates and predictors. Depress Anxiety. 2015;32:763-773. https://doi.org/10.1002/da.22387.
Zhang X, Norris SL, Gregg EW, Cheng YJ, Beckles G, Kahn HS. Depressive symptoms and mortality among persons with and without diabetes. Am J Epidemiol. 2005;161:652-660. https://doi.org/10.1093/aje/kwi089.
van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One. 2013;8:e57058. https://doi.org/10.1371/journal.pone.0057058.
Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31:2383-2390. https://doi.org/10.2337/dc08-0985.
Golden SH, Lazo M, Carnethon M, et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA. 2008;299:2751-2759. https://doi.org/10.1001/jama.299.23.2751.
Chen PC, Chan YT, Chen HF, Ko MC, Li CY. Population-based cohort analyses of the bidirectional relationship between type 2 diabetes and depression. Diabetes Care. 2013;36:376-382. https://doi.org/10.2337/dc12-0473.
Zhuang QS, Shen L, Ji HF. Quantitative assessment of the bidirectional relationships between diabetes and depression. Oncotarget. 2017;8:23389-23400. https://doi.org/10.18632/oncotarget.15051.
Uchendu C, Blake H. Effectiveness of cognitive-behavioural therapy on glycaemic control and psychological outcomes in adults with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabet Med. 2017;34:328-339. https://doi.org/10.1111/dme.13195.
Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:521-529. https://doi.org/10.1001/archpsyc.63.5.521.
Paile-Hyvärinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract. 2003;4:7. https://doi.org/10.1186/1471-2296-4-7.
Amsterdam JD, Shults J, Rutherford N, Schwartz S. Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus. Neuropsychobiology. 2006;54:208-214. https://doi.org/10.1159/000100369.
Huber CA, Reich O. Medication adherence in patients with diabetes mellitus: does physician drug dispensing enhance quality of care? Evidence from a large health claims database in Switzerland. Patient Prefer Adherence. 2016;10:1803-1809. Published 2016 Sep 15. https://doi.org/10.2147/PPA.S115425.
Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38:604-609. https://doi.org/10.2337/dc14-2098.
AlHadi AN, AlAteeq DA, Al-Sharif E, et al. An arabic translation, reliability, and validation of Patient Health Questionnaire in a Saudi sample. Ann Gen Psychiatry. 2017;16:32. Published 2017 Sep 6. https://doi.org/10.1186/s12991-017-0155-1.
Acee AM. Detecting and managing depression in type II diabetes: PHQ-9 is the answer!. Medsurg Nurs. 2010;19:32-38.
Samrah SM, Al-Mistarehi A-H, Aleshawi AJ, et al. Depression and coping among COVID-19-infected individuals after 10 days of mandatory in-hospital quarantine, Irbid, Jordan. Psychol Res Behav Manag. 2020;13:823-830. http://dx.doi.org/10.2147/prbm.s267459.
Kroenke K, Spitzer RL, Williams JB, Löwe B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32:345-359. https://doi.org/10.1016/j.genhosppsych.2010.03.006.
Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. Gen Hosp Psychiatry. 2015;37:67-75. https://doi.org/10.1016/j.genhosppsych.2014.09.009.
Wittkampf KA, Naeije L, Schene AH, Huyser J, van Weert HC. Diagnostic accuracy of the mood module of the patient health questionnaire: a systematic review. Gen Hosp Psychiatry. 2007;29:388-395.
Substance Abuse and Mental Health Services Administration. DSM-5 Changes: Implications for Child Serious Emotional Disturbance [Internet]. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2016 Jun. Table 9, DSM-IV to DSM-5 Major Depressive Episode/Disorder Comparison. https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t5/.
Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol. 2014;29(4):185-196. https://doi.org/10.1097/YIC.0000000000000023.
Gagnon J, Lussier MT, MacGibbon B, Daskalopoulou SS, Bartlett G. The impact of antidepressant therapy on glycemic control in Canadian primary care patients with diabetes mellitus. Front Nutr. 2018;5:47. Published 2018 Jun 12. https://doi.org/10.3389/fnut.2018.00047.
Yu M, Zhang X, Lu F, Fang L. Depression and risk for diabetes: a meta-analysis. Can J Diabetes. 2015;39:266-272. https://doi.org/10.1016/j.jcjd.2014.11.006.
Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165-1173. https://doi.org/10.1111/j.1464-5491.2006.01943.x.
Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the "Top 10" physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med. 2003;45:5-14.
Osborn CY, Egede LE. The relationship between depressive symptoms and medication nonadherence in type 2 diabetes: the role of social support. Gen Hosp Psychiatry. 2012;34:249-253. https://doi.org/10.1016/j.genhosppsych.2012.01.015. Epub 2012 Mar 7.
Lin EH, Rutter CM, Katon W, et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care. 2010;33:264-269. https://doi.org/10.2337/dc09-1068.
Park M, Katon WJ, Wolf FM. Depression and risk of mortality in individuals with diabetes: a meta-analysis and systematic review. Gen Hosp Psychiatry. 2013;35:217-225. https://doi.org/10.1016/j.genhosppsych.2013.01.006.
Wu Y, Levis B, Riehm KE, et al. Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. Psychol Med. 2020;50:1368-1380. https://doi.org/10.1017/S0033291719001314.
El Mahalli AA. Prevalence and predictors of depression among type 2 diabetes mellitus outpatients in Eastern Province, Saudi Arabia. Int J Health Sci (Qassim). 2015;9:119-126.
Sweileh WM, Abu-Hadeed HM, Al-Jabi SW, Zyoud SH. Prevalence of depression among people with type 2 diabetes mellitus: a cross sectional study in Palestine. BMC Public Health. 2014;14:163. Published 2014 Feb 13. https://doi.org/10.1186/1471-2458-14-163.
Sevincok L, Guney E, Uslu A, Baklaci F. Depression in a sample of Turkish type 2 diabetes patients. Eur Psychiatry. 2001;16:229-231. https://doi.org/10.1016/s0924-9338(01)00569-7.
Shehatah A, Rabie MA, Al-Shahry A. Prevalence and correlates of depressive disorders in elderly with type 2 diabetes in primary health care settings. J Affect Disord. 2010;123:197-201. https://doi.org/10.1016/j.jad.2009.09.002.
Yekta Z, Pourali R, Yavarian R. Behavioural and clinical factors associated with depression among individuals with diabetes. East Mediterr Health J. 2010;16:286-291.
Khamseh ME, Baradaran HR, Javanbakht A, Mirghorbani M, Yadollahi Z, Malek M. Comparison of the CES-D and PHQ-9 depression scales in people with type 2 diabetes in Tehran, Iran. BMC Psychiatry. 2011;11:61. Published 2011 Apr 16. https://doi.org/10.1186/1471-244X-11-61.
Saeed AK, Al-Dabbagh TQ. Type 2 diabetes and its association with hypertension and depression in an Iraqi population. Ann Saudi Med. 2003;23:254-259. https://doi.org/10.5144/0256-4947.2003.254.
Al-Maskari M, Al-Shukaili A, Al-Mammari A. Pro-inflammatory cytokines in Omani type 2 diabetic patients presenting anxiety and depression. Iran J Immunol. 2010;7:124-129.
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069-1078.
Levis B, Benedetti A, Ioannidis JPA, et al. Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. J Clin Epidemiol. 2020;122:115-128.e1. https://doi.org/10.1016/j.jclinepi.2020.02.002.
Levis B, Yan XW, He C, Sun Y, Benedetti A, Thombs BD. A comparison of depression prevalence estimates in meta-analyses based on screening tools and rating scales versus diagnostic interviews: a meta-research review. BMC Med. 2019;17:65.
Pettersson A, Boström KB, Gustavsson P, Ekselius L. Which instruments to support diagnosis of depression have sufficient accuracy? A systematic review. Nord J Psychiatry. 2015;69:497-508. https://doi.org/10.3109/08039488.2015.1008568.
Titov N, Dear BF, McMillan D, Anderson T, Zou J, Sunderland M. Psychometric comparison of the PHQ-9 and BDI-II for measuring response during treatment of depression. Cogn Behav Ther. 2011;40:126-136. https://doi.org/10.1080/16506073.2010.550059.
Cameron IM, Cardy A, Crawford JR, et al. Measuring depression severity in general practice: discriminatory performance of the PHQ-9, HADS-D, and BDI-II. Br J Gen Pract. 2011;61:e419-e426. https://doi.org/10.3399/bjgp11X583209.
Reddy P, Philpot B, Ford D, Dunbar JA. Identification of depression in diabetes: the efficacy of Phq-9 and Hads-D. Br J Gen Pract. 2010;60:e239-e245. https://doi.org/10.3399/bjgp10X502128.
Jammal H, Khader Y, Alkhatib S, Abujbara M, Alomari M, Ajlouni K. Diabetic retinopathy in patients with newly diagnosed type 2 diabetes mellitus in Jordan: prevalence and associated factors. J Diabetes. 2013;5:172-179. x. https://doi.org/10.1111/1753-0407.12015.
Al Omari M, Khader Y, Dauod AS, et al. Glycaemic control among patients with type 2 diabetes mellitus treated in primary care setting in Jordan. Prim Care Diabetes. 2009;3:173-179. https://doi.org/10.1016/j.pcd.2009.08.004.
Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65:1132-1140. https://doi.org/10.1111/j.1742-1241.2011.02797.x.
Khassawneh AH, Al-Mistarehi A-H, Zein Alaabdin AM, et al. Prevalence and predictors of thyroid dysfunction among type 2 diabetic patients: a case-control study. Int J Gen Med. 2020;13:803-816. http://dx.doi.org/10.2147/ijgm.s273900.
Gary TL, Crum RM, Cooper-Patrick L, Ford D, Brancati FL. Depressive symptoms and metabolic control in African-Americans with type 2 diabetes. Diabetes Care. 2000;23:23-29.
Gary TL, Baptiste-Roberts K, Crum RM, Cooper LA, Ford DE, Brancati FL. Changes in depressive symptoms and metabolic control over 3 years among African Americans with Type 2 diabetes. Int J Psychiatry Med. 2005;35:377-382. https://doi.org/10.2190/BQ22-4HU0-P6EK-L7YX.
Mathews J, Dange SV, Dutta A, Tilak AV, Shende SS, Das S. An observational study of the effect of escitalopram and etizolam in type 2 diabetes mellitus patients with depression. Int J Basic Clin Pharmacol. 2017;5:2212-2214.
Malone HE, Nicholl H, Coyne I. Fundamentals of estimating sample size. Nurse Res. 2016;23:21-25. https://doi.org/10.7748/nr.23.5.21.s5. PMID: 27188569.